Gilead Sciences’ breast cancer drug receives US FDA approval for third indication
Trodelvy, an antibody–drug conjugate with indications against certain types of cancer, has been approved by the US FDA for a third indication against pre-treated HR+/HER2- metastatic breast cancer.
The US FDA has approved Gilead Sciences’ breast cancer treatment Trodelvy for its third indication against an advanced subtype of breast cancer in patients who have stopped responding to endocrine-based therapy and at least two additional systemic therapies.
Metastatic HER2-low tumours, which account for approximately 50–60% of all breast cancers, are those whose cells contain lower levels of HER2 proteins on the cell surface. This type of breast cancer has historically been difficult to treat, and almost one-third of early-stage breast cancer cases eventually become metastatic. Patients with HER2-low/negative metastatic disease present a 5-year survival rate of only 30%. Primary treatment options include endocrine-based therapies but once the cancer is resistant to these therapies, treatment options become limited to single-agent chemotherapies, though the prognosis continues to remain poor. In a study termed the TROPiCS-02 study, Trodelvy demonstrated a survival benefit of 3.2 months versus single-agent chemotherapy that was statistically significant and clinically meaningful. A 34% reduction of disease progression risk or death was also established by researchers.
Hope Rugo, professor of medicine and Director, Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, stated: “Despite decades of advances, people living with pre-treated HR+/HER2- metastatic breast cancer need new treatment options. Nearly all people with this type of breast cancer will eventually develop resistance to endocrine-based therapies and progress on available chemotherapies...This approval is significant for the breast cancer community. We have had limited options to offer patients after endocrine-based therapy and chemotherapy, and to see a clinically meaningful survival benefit of more than 3 months with a quality-of-life benefit for these women is exceptional.”
Trodelvy, an antibody–drug conjugate, operates by targeting cell surface antigens known as Trop-2 on cancer cells. In the US, it is currently approved for the treatment of inoperable localised or metastatic triple-negative breast cancer and locally advanced or metastatic urothelial cancer in adults who have received prior treatments. Further developments are examining potential investigational use in other metastatic cancer populations and a range of tumour types where Trop-2 is highly expressed. These include metastatic small cell lung cancer, head and neck cancer, and endometrial cancer.
Chairman and CEO of Gilead Sciences Daniel O’Day added: “We are pleased that Trodelvy [can] now provide new hope for people living with pre-treated HR+/HER2- metastatic breast cancer, building on the transformative role that Trodelvy is already playing for people with metastatic triple-negative breast cancer.”
Sources:
1. U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer (gilead.com)
2. Gilead's breast cancer drug gets U.S. FDA approval for third indication | Reuters
3. Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer - NCI
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance